INTRODUCTION {#s1}
============

With an expected 53,070 new cases in 2016, pancreatic cancer (PC) is one of the major causes of cancer death in the United States \[[@R1]\]. For four decades, the 5-year survival rate for PC has hovered around 5% \[[@R2]\]. In addition to its silent nature and tendency for late discovery, PC shows unusual resistance to chemotherapy and radiation. The use of radiation therapy (RT) in PC treatment is multi-fold: (i) RT after surgery prevents tumor relapse or recurrence, (ii) RT before surgery, along with chemotherapy, shrinks and makes removing borderline resectable tumors easier, (iii) RT can be the main treatment, combined with chemotherapy, for locally advanced and unresectable cancers; (iv) RT relieves pain in patients with advanced cancers, and; (iv) RT can be used as the prime modality for people who are not healthy enough for other treatments \[[@R3], [@R4]\]. However, clinical trials that investigated the benefit of RT, either alone or as part of chemo-RT, have shown equivocal clinical outcomes in patients with PC \[[@R4], [@R5]\]. Only 20% of primary PCs show a determinate response to RT \[[@R4], [@R6]\]. The lack of clinical efficacy of RT mandates the investigation of methods to overcome radiation resistance in PC. To that end, radio-sensitizing PC cells could significantly benefit patients diagnosed with resectable disease who suffer from local and/or distant failure post-resection \[[@R7], [@R8]\]. The need to defeat PC\'s induced radio-resistance and to potentiate therapeutic radiation highlights the necessity of elucidating the underlying mechanisms of PC.

Adding to the complexity, metastatic disease develops after surgery combined with pre/post radiotherapy (RT). However, the onset and orchestration of the sequential functional events of metastasis, including malignant cell release from the primary tumor site, inhabitation, and clonal expansion at distant sites, is poorly understood \[[@R9]\]. Initial event of metastasis originates in the primary tumor microenvironment, where intercellular molecular signaling cross talk between the tumor, surrounding stroma, and adjacent tissues leads to extracellular matrix rearrangement, cell motility enhancement, and proliferation promotion. The genetic rearrangements that occur in cancer cells drive uncontrolled growth, aberrant replication and sustained angiogenesis, and regulate anti-growth signals and evade apoptosis; these rearrangements collectively orchestrate progressive metastatic disease \[[@R10]\]. Based on the concept of multistage carcinogenesis in PC, continuous acquisition of these genetic rearrangements in therapy-resistant cancer cells is instrumental for post-surgical recurrence and/or metastasis. Since numerous genes are engaged in the sequential processes of tumor dissemination \[[@R11]--[@R18]\], understanding the comprehensive TIM transcriptome in therapy-resistant surviving PC cells is crucial. Accordingly, the objective of this study is to understand the comprehensive TIM transcriptome in therapy-resistant surviving PC cells and identify the genetic determinants that govern radio-resistance and subsequent tumor recurrence and dissemination. This study identified two such genetic determinants, CXCR4 and COX2, in a panel of radio-resistant, genetically diverse PC cells. CXCR4 is the only receptor that is expressed in the normal pancreas, PC cells, and all pancreatic tumor specimens \[[@R19]\]. Likewise, researchers have reported \> 70% COX-2 expression in clinical PC \[[@R20]--[@R22]\]. We investigated the influence of radiation-induced CXCR4 and COX2 in dictating the metastatic state of surviving PC cells.

The development of drug deliverables targeting such genetic determinants is imminent and could shift the current therapeutic approach in progressive PC. The health care industry heavily relies on natural products \[[@R23]\], as these derivatives constitute \> 50% of drugs in clinical use. In parallel to the NCI\'s ongoing probable drug screening of \>100,000 extracts against tumor systems \[[@R24]\], extensive research to identify anticancer deliverables from various marine floral compounds, including seaweeds, is underway \[[@R25]\]. The anticancer potential of seaweeds that contain large amounts of polyphenols (catechin, epicatechin, EGCG, gallic acid) has been well documented \[[@R26], [@R27]\]. Further, studies have demonstrated the anti-proliferative \[[@R28]\], tumor-regressing \[[@R29]\], and metastasis-inhibiting \[[@R30]\] efficacy of seaweed polyphenols. A linear and directly proportional relationship between the anti-carcinogenic activity and antioxidant activity of polyphenols has been documented in many *in vivo* models \[[@R29], [@R31]--[@R33]\]. In assorted tumor models, researchers have recognized the benefit of seaweed extracts in effectively suppressing the functional cellular events that drive tumor progression, including tumor cell growth, cell-cycle release, proliferation, survival, DNA repair, angiogenesis, and metastasis \[[@R34]--[@R39]\]. Recently, our *in vitro* studies screened a panel of polyphenols derived as polarity gradient extractions from five different seaweed species for their efficacy against PC \[[@R40]\], and recognized three deliverables with high impact on impeding autophagy signaling \[[@R41]\] and PC cancer stem cell status \[[@R42]\]. Hence, these fractions could be clinically translatable in this setting. We hypothesize that one such fraction, *Hormophysa triquerta* polyphenol (HT-EA), will result in the inhibition of crucial genetic determinants of the TIM phenotype. Delineating such efficacy in radio-resistant PC cells will identify a 'drug deliverable' that not only radio-sensitizes PC cells, but will also potentiate the benefit of RT in the treatment of this deadly disease.

RESULTS {#s2}
=======

Radiotherapy prompts tumor invasion and metastasis transcriptome activation in resistant PC cells {#s2_1}
-------------------------------------------------------------------------------------------------

To define the radio-responsive TIM-related signaling in PC cells, we investigated the alterations in mRNA levels for 93 well-characterized TIM molecules ([Table S1](#SD2){ref-type="supplementary-material"}) in genetically diverse human PC cells exposed to clinical RT. QPCR profiling revealed unique amplification signatures across treatment groups and cell lines. Profile-to-profile expression distinctions were normalized with in-house controls (HPRT-1, GAPDH, and/or β-actin), hierarchically clustered (complete linkage) with Gene Cluster (<http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm>), and examined using Maple Tree (v0.2.3.2 Beta, [rana.lbl.gov/EisenSoftware.htm](http://rana.lbl.gov/EisenSoftware.htm)), which provides self-organizing maps of distinctive gene expression profiles for every condition and cell line investigated ([Figure S1](#SD1){ref-type="supplementary-material"}). Overall, RT resulted in the activation of 36, 53, 29, and 42 TIM molecules in surviving Panc-1, Panc-3.27, BX-PC3, and MiaPaCa-2 cells, respectively. Interestingly, cells→genes traverse analysis identified cell-line-independent activation of 10 genes (across 4 cell lines), 15 genes (in 3 cell lines), and 24 genes (in 2 cell lines).

![Alteration of tumor invasion metastasis transcriptome in PC cells surviving after fractionated RT\
Clinical doses of radiation (2 Gy/Day for 5 days for a total dose of 10 Gy) significantly induced (≥ 2 fold upregulation) tumor invasion and metastasis transcriptome in surviving *Panc-1*, *Panc-3.27*, *MiaPaCa-2*, and *BxPC-3* cells. Two genes, CXCR4 and PTGS2, showed consistent *cell-line-independent* upregulation. Quantitative transcriptional expression of 93 TIM molecules were assayed using custom-archived QPCR profiling.](oncotarget-08-5717-g001){#F1}

Applying stringent criteria, RT significantly increased the expression of 30, 50, 15, and 38 TIM genes in Panc-1, Panc-3.27, BX-PC3, MiaPaCa-2 cells (Figure [1](#F1){ref-type="fig"}). Two genes, *CXCR4* and *PTGS2,* showed *cell-line-independent* upregulation after FIR exposure. Thirteen genes, *Birc3*, *CTSD*, *CTSL1*, *FGFR4*, *IL1β*, *MCAM*, *Met*, *Metap2*, *MMP10*, *MMP13*, *MTA2*, *Myc*, and *NF2* showed cell-line-independent activation in at least three cell lines. After RT, a set of 26 TIM genes (*Adamts1*, *Aldh3A1*, *kRas*, *Casp8*, *Kynu*, *CD44*, *CD82*, *CST7*, *CTSB*, *CTGF*, *CTSK*, *TP53*, *HMGB1*, *CXCL12*, *IL13Ra2*, *FLT1*, *MMP-2*, *-7*, *-14*, *MGAT5*, *NEDD9*, *NME-1*, *-4*, *VEGFA*, *SPP1*, *SYK*) were upregulated in two cell lines. Distinctively, a small subset of genes showed *cell-line-dependent* activation in Panc-1 (*HTATIP2*, *Serpine 1*), Panc-3.27 (*FLT4*, *HGF*, *Hras*, *ID1*, *IGFBP7*, *ISG20*, *ITGA7*, *MMP-3*, *-9*, *NME-2*, *-5*, *Pax5*, *PDGFA*, *PLAUR*, *PTEN*, *TDD1*, *TGFβ1*, *Tmip-2*, *-4*), BxPC-3 (*HDAC1*, *MAP2K4*), and MiaPaCa-2 (*CCNE2*, *CCR7*, *CDH-1*, *-11*, *Col4A2*, *Jag1*, *Kiss1*, *MMP1*, *MTSS1*, *Runx1*) cells. These results highlight the induction of TIM-related transcripts in radio-resistant PC cells. Further, these data identify the *cell-line-independent* and *cell-line-dependent* upsurge in TIM transcriptional responses in PC cells after RT.

HT-EA target therapy-orchestrated onset of TIM transcription in human PC cells {#s2_2}
------------------------------------------------------------------------------

We investigated the alterations in the transcription of TIM molecules in human PC (Panc-1, Panc-3.27, BxPC-3, MiaPaCa-2) cells that were pretreated with HT-EA and exposed to radiation. Pre-treating cells with HT-EA inhibited 15 (of 30), 44 (of 50), 12 (of 15), and 26 (of 38) FIR-induced TIM molecules in Panc-1, Panc-3.27, BxPC-3, and MiaPaCa-2 cells, respectively (Figure [2](#F2){ref-type="fig"}). Interestingly, treatment with HT-EA repressed radiation-induced *CXCR4* across all cell lines investigated. In addition, *PTGS2 (COX2)*, upregulated across PC cells after RT, was completely suppressed with HT-EA (Figure [2](#F2){ref-type="fig"}). Moreover, cell-line-independent inhibition of *Birc3*, *CTGF*, *CTSD*, *FGFR4*, *IL1β*, *Metap2*, *MMP10* (3 cell lines), *ADAMTS1*, *Aldh3A1*, *Casp8*, *CD82*, *CST7*, *CTSB*, *CTSL1*, *IL13Ra2*, *MMP-7*, *-13*, *-14*, *MGAT5*, *MTA2*, *MCAM*, *MYC*, *NEDD9*, *NF2*, and *NME-1* (2 cell lines) were observed with HT-EA treatment. Conversely, *HTAIP2*, *VEGFA* (Panc-1), *FLT-1*, *-4*, *HGF*, *HMGB1*, *HRAS*, *ID1*, *IGFBP7*, *ISG20*, *ITGA7*, *MMP-2*, *-3*, *NME-2*, *-5*, *PAX5*, *PDGFA*, *PLAUR*, *PTEN*, *SYC*, *TIMP-4* (Panc-3.27), *HDAC1*, *MAP2K4*, *TP53* (BxPC-3), *CCNE2*, *CCR7*, *MET*, *MTSS1*, and *NME4* (MiaPaCa-2) showed *cell-line-dependent* inhibition after HT-EA pretreatment.

![HT-EA alleviates RT-associated activation of tumor invasion and metastasis transcriptome in surviving PC cells\
Histograms of QPCR profiling comparison analysis showing the *HT-EA*-associated regulation of fractionated radiation-induced tumor invasion and metastasis transcriptome in surviving *Panc-1*, *Panc-3.27*, *BxPC-3*, and *MiaPaCa-2* cells.](oncotarget-08-5717-g002){#F2}

HT-EA regulates translation of CXCR4, COX2, and other crucial TIM targets (β-catenin, MMP9, Ki-67, NKX3.2, PhPT1, MEGF10, GRB10) in residual PC {#s2_3}
-----------------------------------------------------------------------------------------------------------------------------------------------

To investigate whether HT-EA regulates radiation-induced common targets (CXCR4, COX2) and other critical proteins (β-catenin, MMP9, Ki-67, NKX3.2, PhPT1, GRB10) that are instrumental in PC progression after therapy, we examined their alterations in PC cells that were selectively exposed to RT, with or without a daily dose of HT-EA. IHC staining consistency across samples was achieved by TMA construction (Figure [3A](#F3){ref-type="fig"}) utilizing histopathological evaluations of individual H&E stained tumor tissues, coupled with automated IHC. C-X-C chemokine receptor type 4 (CXCR4) IHC staining exhibited baseline positivity in mock-irradiated controls (Figure [3B](#F3){ref-type="fig"} & [3C](#F3){ref-type="fig"}). Selective CXCR4 localization was observed in the plasma membrane (see pullout in Figure [3B](#F3){ref-type="fig"}). We observed no staining when the no-primary negative control for CXCR4 was used. IHC revealed strong positivity and abundant presence (\~80% of cells) of CXCR4 in residual PC after RT (Figure [3B](#F3){ref-type="fig"} & [3C](#F3){ref-type="fig"}). However, HT-EA treatment completely (*P* \< 0.05) suppressed CXCR4 in residual PC (Figure [3C](#F3){ref-type="fig"}). Figure [4A](#F4){ref-type="fig"} portrays the expression profiles of COX2 (PTGS2) in PC exposed to clinical FIR (compared with mock-IR controls), with or without HT-EA treatment. Compared with the stromal cells, we observed strong COX2 positivity in tumor cells. At the sub-cellular level, COX2 is abundant in cytoplasm, with weak membranous localization (see pullout in Figure [4A](#F4){ref-type="fig"}). Although COX2 was detectable under all conditions, strong (*P* \< 0.01) and abundant positivity was observed in residual PC (Figure [3C](#F3){ref-type="fig"}). There was a substantial variance in COX2 expression between the group that received radiation alone and the group that received radiation and HT-EA (Figures [3C](#F3){ref-type="fig"} & [4A](#F4){ref-type="fig"}). These modifications in CXCR4 and COX2 expression in response to RT in the presence and absence of HT-EA treatment corroborated well with the transcriptional modifications observed with QPCR profiling.

![HT-EA mitigates RT-associated translation of tumor invasion and metastasis targets in residual PC\
**A**. Representative microphotographs from hematoxylin & eosin stained PC tissue microarray (TMA) constructed with xenografts (established from MiaPaCa-2) exposed to mock-irradiation or fractionated irradiation, with or without HT-EA treatment. Pullout shows the staining pattern (20x magnification). **B**. Representative microphotographs from CXCR4-stained PC tissue microarray (TMA) constructed with xenografts exposed to mock-irradiation or fractionated irradiation, with or without HT-EA treatment. Pullout shows the staining pattern (20x magnification). **C**. Aperio TMA quantitation analysis showing protein-specific positivity magnitudes (mean + *SD*) in mock-irradiated PC xenografts, and residual PC after clinical RT, with or without HT-EA treatment. Group-wise comparisons were made using Two-way ANOVA with Bonferroni\'s post-hoc correction.](oncotarget-08-5717-g003){#F3}

![HT-EA mitigates RT-associated translation of COX2, β-catenin, MMP9, and Ki-67 in residual PC\
Representative microphotographs from **A**. Cox2-, **B.** β-catenin-, **C**. MMP9-, and **D**. Ki-67- stained PC tissue microarray (TMA) constructed with xenografts (established from MiaPaCa-2) exposed to mock-irradiation or fractionated irradiation, with or without HT-EA treatment. The pullout in each panel represents the corresponding Ab staining pattern in 20x magnification showing the protein-specific cellular localization. Please see Figure [3C](#F3){ref-type="fig"} for Aperio TMA quantitation analysis of COX2-, β-catenin-, MMP9-, and Ki-67-specific positivity magnitudes (mean + *SD*) in mock-irradiated PC xenografts, and residual PC after clinical RT, with or without HT-EA treatment.](oncotarget-08-5717-g004){#F4}

β-catenin (Cadherin-associated protein and beta 1) IHC staining revealed predominant plasma membrane localization (see pullout in Figure [4B](#F4){ref-type="fig"}). Compared with the baseline expression in mock-IR controls, we observed strong and abundant ( \> 90% of the cells) β-catenin expression (*P* \< 0.001) in residual PC after clinical RT (Figures [3C](#F3){ref-type="fig"} & [4B](#F4){ref-type="fig"}). β-catenin immunoreactivity was completely reduced *(P* \< 0.001) to near basal levels (Figure [3C](#F3){ref-type="fig"} & [4B](#F4){ref-type="fig"}) in all PC cores from HT-EA-treated animals. Figure [4C](#F4){ref-type="fig"} shows representative IHC results for Matrix metallopeptidase 9 (MMP-9) in PC cells that received RT, with or without HT-EA pre-treatment. MMP-9 expression was stronger and selective in the cytoplasm, with some weak positivity in the nucleus (see pullout in Figure [4C](#F4){ref-type="fig"}). While mock-IR controls exhibited measurable levels of MMP-9, we observed strong MMP-9 positivity (*P* \< 0.001) in residual PC after RT. Weak positive MMP-9 expression was observed with HT-EA treatment (Figure [3C](#F3){ref-type="fig"} & [4C](#F4){ref-type="fig"}). Likewise, Ki-67 positivity was detected under all conditions. IHC staining revealed a strong nuclear localization (see Figure [4D](#F4){ref-type="fig"} pullout). Ki-67 positivity ranged from 48.35% in mock-IR control to 98.70% of residual tumors (Figure [3C](#F3){ref-type="fig"}). HT-EA treatment produced fewer Ki-67-positive epithelial cells (48.38%; Figures [3C](#F3){ref-type="fig"} and [4D](#F4){ref-type="fig"}).

The PhPT1 (Phospho-histidine phosphatase 1) IHC staining profile for PC specimens after RT, with or without HT-EA treatment, are presented in Figure [5A](#F5){ref-type="fig"}. No traceable PhPT1 immunoreactivity was observed in control (mock-IR) conditions, consistent with the documented low expression of PhPT1 in PC ( [www.proteinatlas.org](http://www.proteinatlas.org)). Radiation-exposed PC cells revealed a detectable, yet weak, cytoplasmic localization of PhPT1 (see Figure [5A](#F5){ref-type="fig"} pullout). However, RT-associated induction in PhPT1 localization was completely reduced with HT-EA treatment (Figures [3C](#F3){ref-type="fig"} & [5A](#F5){ref-type="fig"}). IHC analysis of BAPX1 (NK3 homeobox 2, NKX3.2) revealed baseline positivity in mock-IR controls. Bapx1 was mostly localized in the nucleus (see Figure [5B](#F5){ref-type="fig"} pullout). After RT, Bapx1 expression was strongly positive and present in 93.92% of the PC cells lingering after treatment (Figure [3C](#F3){ref-type="fig"} & [5B](#F5){ref-type="fig"}). Conversely, HT-EA treatment in conjunction with RT resulted in a significant (*P* \< 0.001) reduction in Bapx1 levels in residual PC (Figure [3C](#F3){ref-type="fig"} & [5B](#F5){ref-type="fig"}).

![HT-EA mitigates RT-associated translation of PhPT-1, BAPX, MEGF-10, and GRB-10, in residual PC\
Representative microphotographs from **A**. PhPT-1, **B**. BAPX, **C**. MEGF-10, and **D**. GRB-10-stained PC tissue microarray (TMA) constructed with xenografts (established from MiaPaCa-2) exposed to mock-irradiation or fractionated irradiation, with or without HT-EA treatment. The pullout in each panel represents the corresponding Ab staining pattern in 20x magnification, showing the protein-specific cellular localization. Please see Figure [3C](#F3){ref-type="fig"} for Aperio TMA quantitation analysis of PhPT-1-, BAPX, MEGF-10-, and GRB-10-specific positivity magnitudes (mean + *SD*) in mock-irradiated PC xenografts, and residual PC after clinical RT with or without HT-EA treatment.](oncotarget-08-5717-g005){#F5}

Likewise, cellular localization levels of Multiple EGF-like-domains 10 (MEGF10) were examined in PC xenografts exposed to RT, with and without polyphenol treatment (Figure [5C](#F5){ref-type="fig"}). MEGF10 immunoreactivity showed marginal positivity in control (mock-IR) specimens (Figure [3C](#F3){ref-type="fig"}), consistent with reported levels in human PC ([www.proteinatlas.org](http://www.proteinatlas.org)). Conversely, the residual PC cells exhibited up to 44.71% immunoreactivity for MEGF10 localization. MEGF10 positivity appeared brown in color, and was mostly localized in the plasma membrane in a spotted pattern (see Figure [5C](#F5){ref-type="fig"} pullout). We observed a significant (*P* \< 0.001) inhibition of induced MEGF10 expression in residual PC tissues with HT-EA treatment (Figures [3C](#F3){ref-type="fig"} & [5C](#F5){ref-type="fig"}). Further, we examined GRB10 (Growth factor receptor-bound protein 10), a protein that is highly expressed in human PC ([www.proteinatlas.org](http://www.proteinatlas.org)), in PC exposed to RT, with and without HT-EA treatment (Figure [5D](#F5){ref-type="fig"}). Mock-irradiated PC tumors showed low GRB10 immunoreactivity. GRB10 positivity was intense and present in 98.51% of the PC cells that survived RT (Figure [3C](#F3){ref-type="fig"}). GRB10 positivity appeared granular and dark brown in color, and was primarily localized in the cytoplasm (see Figure [5D](#F5){ref-type="fig"} pullout). Treatment with HT-EA significantly (*P* \< 0.001) reduced the radiation-induced GRB10 expression in PC tissues. These observations demonstrate the efficacy of HT-EA in mitigating therapy-responsive induction of β-catenin, MMP9, Ki-67, NKX3.2, PhPT1, GRB10, and MEGF10 in residual PC.

HT-EA deters the radiotherapy-induced CXCR4/COX2 facilitated metastatic state of the resistant PC cells {#s2_4}
-------------------------------------------------------------------------------------------------------

Delineating whether RT-associated transcriptional→translational increase of CXCR4 and COX2 mediates the metastatic state of the surviving PC cells, and whether treatment with HT-EA deters such a response, we examined the associated modifications in two hallmarks of metastasis coupled with gene knock-in/knock-out approaches. For this, human PC (MiaPaCa-2, Panc-1) cells exposed to either mock-IR or IR, with or without HT-EA treatment, were examined for modulations in tumor cell migration and invasion capabilities. To define the role of COX2 and/or CXCR4 in the IR-induced metastatic state of the cells, COX2- or CXCR4-silenced PC cells were then exposed to mock-IR or IR. To identify whether HT-EA affects PC cell dissemination destiny by selectively targeting CXCR4/COX2, we assessed the alterations in tumor cell migration and invasion after ectopic expression of CXCR4/COX2 in PANC-1 and MiaPaCa-2 cells treated with HT-EA. Cell migration analysis under proliferation-controlled conditions revealed marginal migration in mock-irradiated controls of Panc-1 (Figure [6A](#F6){ref-type="fig"} & [6B](#F6){ref-type="fig"}) cells. However, we noticed a profound surge in the migration of cells that survived IR exposure, as evidenced by the complete disarray of the cells. It is pertinent to mention that, since the experiments were performed under strict proliferation control conditions, the complete disarray of the wound represents the robust movement of the cells (Figure [6A](#F6){ref-type="fig"} & [6B](#F6){ref-type="fig"}). Interestingly, treating these cells with HT-EA completely reversed radiation-induced cell migration (Figure [6A](#F6){ref-type="fig"} & [6B](#F6){ref-type="fig"}) and demonstrates the tumor cell migration inhibition potential of HT-EA in this setting. Silencing CXCR4 or COX2 remarkably reversed the induced cell migration in surviving cells (Figure [6A](#F6){ref-type="fig"} & [6B](#F6){ref-type="fig"}), identifying the definitive role of IR-induced CXCR4 and/or COX2 in tumor cell migration. Conversely, forced expression of CXCR4 or COX2 simulated the RT response, with complete disarray of cells (Figure [6A](#F6){ref-type="fig"} & [6B](#F6){ref-type="fig"}), defining their direct role in induced cell migration. Treating the cells with HT-EA reverted the forced expression-induced cell migrations (Figure [6A](#F6){ref-type="fig"} & [6B](#F6){ref-type="fig"}), demonstrating that HT-EA deters tumor cell migration by selectively targeting radiation-induced CXCR4 and COX2.

![RT-associated activation of CXCR4 and COX-2 determined the metastatic state of the surviving PC cells\
**A**. Representative whole images of cell migration assay (mock-IR and IR) and the representative images of migrated cells in the cell seed stopped areas (wound) taken after 0 and 24h of human Panc-1 cells exposed to either mock-irradiation or radiation with and without HT-EA treatment, forced expression of COX2 or CXCR4 with/without HT-EA treatment, after silencing COX2/CXCR4, after HT-EA treatment alone or, after silencing COX2/CXCR4 and exposed to FIR. **B**. Panc-1 cells migrated to seed stopped area (wound) and **C**. Matrigel-invaded MiaPaCa-2 and Panc-1 cells (mean + *SD*) showing 1) heightened migratory and invasive potential of cells that survive RT; 2) complete inhibition of IR-induced migration/invasion potential with HT-EA treatment, by muting IR-induced CXCR4 or COX2; 3) high migration/invasion capacity in CXCR4 or COX2 expressed cells, and; 4) complete inhibition of CXCR4-/COX2-induced migratory/invasive capabilities with HT-EA treatment. Expression of CXCR4 or COX-2 (Origene) was carried out using TurboFectin 8.0 and CXCR4 or COX-2 silencing with shRNA (MISSION^®^ shRNA, Sigma-Aldrich) following standard protocols. Invasion assays were performed using the BD Matrigel invasion assay, following standard protocols. Quantification of invaded cells was performed using Image Quant colony count analysis software. Group-wise comparisons were examined by ANOVA with Bonferroni\'s post-hoc corrections using GraphPad PRISM software. A *P* value of \< 0.05 was considered significant.](oncotarget-08-5717-g006){#F6}

Results from a matrigel invasion assay identified heightened tumor cell invasion in RT-resistant MiaPaCa-2 and Panc-1 Cells (Figure [6C](#F6){ref-type="fig"}). However, pretreating these cells with HT-EA significantly (*P* \< 0.001) inhibited therapy-induced invasion. Further, muting COX2 or CXCR4 completely (*P* \< 0.001) deterred the induced invasion capabilities of surviving PC cells, highlighting their intrinsic therapy-associated switch in the metastatic state. Moreover, forced expression of CXCR4 and COX2 resulted in a significant increase in tumor cell invasion (Figure [6](#F6){ref-type="fig"}). Treating the cells with HT-EA reversed the COX2 or CXCR4 expression-associated increase in tumor cell invasion. Together, these data demonstrate that HT-EA selectively targets RT-induced CXCR4/COX2-dependent heightened invasion in surviving PC cells.

DISCUSSION {#s3}
==========

In cancer patients, metastasis remains the major cause of death \[[@R43], [@R44]\]. Patients with PC present with progressive metastatic disease at diagnosis, with minimal response to chemotherapy and RT \[[@R45]\]. However, the onset of PC metastasis, particularly after first-line therapy, and the molecular mechanisms that underlie therapy resistance, tumor progression, and dissemination are poorly understood. Identifying drug deliverables that can target tumor progression after therapy will have a momentous impact on the treatment of PC. The results presented here demonstrate the initiation of a robust invasion/metastasis signaling response in the PC cells that survive RT. Studies have demonstrated the existence of functional interlinks between the sequential cellular events, such as signaling response, DNA damage recognition, and induced repair, in PC cells that survive therapy. Surviving tumor cells after RT exhibit initiation of hyperactive (oncogenic) survival and activation of the invasion/metastasis signal transduction pathways \[[@R46]--[@R58]\].

The results present a blueprint of the modulation of tumor cell invasion/metastasis transcriptome (93 genes) in human PC cells after clinically relevant, fractionated RT. The data show the complex pattern of TIM transcriptome elevation after RT, with a clear indication of a 'cell-line-independent' response. Further, we demonstrated significant clinical benefits of a seaweed polyphenol fraction in mitigating the therapy-associated activation of TIM transcriptomes *in vitro* and functional cellular localization of crucial players *in vivo*. Our study examined (a) a comprehensive panel of TIM signaling molecules after clinical RT in a panel of genetically diverse PC cells, (b) the potential of a proven anti-PC bioactive fraction of seaweed polyphenols in targeting the therapy-associated TIM transcriptome, (c) the cellular localization of key functional tumor invasion and metastasis responses driving CXCR4, COX2, β-catenin, KI-67, NKX3.2, GRB10, MEGF10, PhPT-1, and MMP-9 in established PC residual tumors after RT, (d) the clinical benefits of HT-EA in reverting the therapy-associated regulation of β-catenin, KI-67, NKX3.2, GRB10, Megf10, PhPT-1, and MMP-9 in residual tumors, (e) the intrinsic influence of radiation-induced COX2 and CXCR4 in the heightened metastatic state of the PC cells that survive radiation, and (f) the efficacy of HT-EA in selectively inhibiting radiation-induced COX2- and/or CXCR4-dependent heightened tumor cell migration and invasion. The 93 genes that we examined are functionally characterized as pro-invasion and -metastasis molecules. Hence, upregulation of these genes reflects the functional response. To that end, here we focus the discussion on gene profiles and TIM signature, with an in-depth assessment of cell-line-independent candidates and the benefits of HT-EA as an anti-metastatic drug deliverable.

Metastasis, the process by which tumor spreads or disseminates to distant organs, is a well-programmed, tightly regulated, complex, sequential process. Local invasion, the first step, requires cell release that defies cellular adhesion and prompts cell motility, which facilitates tumor cell invasion into the adjacent tissues. This is followed by the invasion of cancer cells through the basal membrane, blood, and lymphatic vessel endothelium (intravasation), thus entering the circulation. In combination with circulating leukocytes and platelets, the surviving circulating tumor cells assemble tumor emboli and are arrested at remote locations. At these sites, tumor cells invade out of the vessels (extravasation) and occupy the distant site. The continuous ongoing acquisition of genetic and epigenetic changes in these tumor cells, coupled with favorable microenvironment conditions, prompts cell proliferation and the angiogenic response that could lead to the development of metastatic tumor.

Our results document a comprehensive, cell-line-independent induction of TIM molecules in human PC cells after RT. Activation profiles of TIM molecules were fairly high in Panc-3.27 cells compared with other cell lines, presumably due to the elemental variations in radiation-response between these genetically diverse PC cells. Although researchers have recognized the instrumental role of select TIM molecules in PC, here for the first time, we report the comprehensive alterations of TIM molecules in surviving PC cells. Two genes, *CXCR4* and *COX-2*, stood out after IR. Induction of these two molecules identified them as the prime mechanisms that could drive PC metastasis after therapy. A number of additional molecules that showed elevated activation after RT in \> 2 cell lines are also potential targets for sensitization.

The critical role of CXCR4 in influencing every stage of metastasis, including tumor cell migration, growth, invasion, and angiogenesis, has been recognized \[[@R19], [@R59]--[@R62]\]. Further, studies have identified that CXCR4 is the only receptor that is expressed in healthy human pancreas, PC cells, and 100% of PC specimens \[[@R19]\]. CXCR4 positivity and/or its heightened expression have been shown to significantly correlate with PC progression and dissemination and with a substantial reduction in OS \[[@R63]\]. The present study confirms a consistent and *cell*-*line-independent* transcriptional activation of CXCR4 in PC cells surviving first-line RT. Although CXCR4 is mutagenic for PC and other tumor cells \[[@R60]\], a recent study demonstrated that CXCR4 could also amplify the metastatic state of PC cells \[[@R19]\]. Consistently, silencing CXCR4 has been shown to inhibit cancer migration \[[@R64]\], including migration in PC \[[@R63]\]. More importantly, blocking CXCR4 has been shown to hinder PC carcinogenesis by impeding the cell cycle and cell colony formation \[[@R63]\]. Herein, our results demonstrated that CXCR4 transcription is activated in all genetically diverse PC cells that survive RT, corresponding with a translational increase in residual PC tumors, and that radiation-induced CXCR4 mediates the migration and invasion of surviving PC cells. New to science, these findings also identify that HT-EA can not only cause a significant and consistent inhibition of CXCR4 transactivation and translation in therapy-resistant PC cells, but also deters the CXCR4-dependent alterations in the metastatic state of the cells. In this regard, HT-EA targeting CXCR4 could be highly beneficial in the mitigation of metastasis after therapy and/or the onset of secondary oncogenesis in this setting.

Evidence suggests an important role of COX-2 in the initiation and evolution of many tumors \[[@R21], [@R65]--[@R69]\], including PC \[[@R20], [@R21]\]. COX-2, a catalytic enzyme that plays a critical role in the synthesis of prostaglandins \[[@R70]\], has been shown to be upregulated in \> 70% of human PC \[[@R20]--[@R22]\]. In many cancers, heightened COX-2 levels have been shown to correlate with high levels of intratumoral prostaglandin E2 (PGE2) \[[@R71]--[@R73]\]. PGE2 was recently shown to upregulate invasive potential \[[@R74]\]. Studies demonstrating the activation of matrix metalloproteinases and the associated increase in invasive physiognomies with ectopic expression of COX-2 further revealed the influence of COX-2 in tumor invasion \[[@R75]\]. Most studies have examined the role of COX-2 in PC tumorigenesis and progression. However, to our knowledge, the current study is the first observation demonstrating the therapy-triggered activation of COX-2 in surviving cells. The results presented here established a consistent increase in COX-2 activation in all PC cell lines investigated. Biologically, COX-2 upregulation has been shown to resist programmed and/or induced cell death \[[@R76]\], to dictate the metastatic state in cancer cells \[[@R75]\], and to stimulate angiogenic events \[[@R77]\]. Collectively, these COX-2 upregulation-driven biological events play critical roles in tumor evolution. Our results demonstrating elevated COX-2 expression in all PC cell lines after IR and in residual tumors recognize COX-2 as a definitive target for radio-sensitization. Moreover, our findings show that induced COX-2 mediates, at least in part, the tumor cell metastatic potential. Demonstrating the efficacy of HT-EA in inhibiting the COX-2-dependent heightened metastatic state of therapy-resistant PC cells defines the benefit of this fraction in effective prevention and/or treatment of PC relapse and recurrence.

Although the benefits of seaweed constituents in cancer treatment are beginning to be discovered, ours is the first group to show the benefits of sequentially extracted polyphenol fractions in cancer medicine, particularly as treatments against PC \[[@R40]\]. Utilizing a comprehensive approach, we identified three fractions with high levels of activity: SA-EA, PT-EA, and HT-EA \[[@R41], [@R42]\]. Our results further demonstrate the advantage of one such promising fraction in preventing PC invasion and metastasis when used in conjunction with RT, by selectively targeting the therapy-driven molecular switches. Strikingly, HT-EA attenuated the CXCR4 and COX-2 molecules in therapy-resistant cells. Upon close examination of the data, HT-EA was noted to have a unique inhibitory signature on every panel of RT-induced cell-line-independent TIM molecules (see Results). Taken together, the data indicate that seaweed extract prompts a direct and definite inhibitory effect on invasion and metastasis in residual PC settings. This work provides a foundation for more detailed mechanistic investigations and translation into the clinic setting.

We utilized a preclinical PC residual tumor model that incorporates clinically mimicking fractionated RT selectively delivered to human PC xenografts, to identify HT-EA\'s efficacy in the regulation of TIM functional response molecules. To our knowledge, this is the first attempt of such an approach to determine the therapeutic response in PC. We observed increased expression of β-catenin, a crucial player in canonical Wnt signaling, in residual PC tumors. Studies have demonstrated the critical role of β-catenin in cancer cell proliferation, dissemination, and other key functional events \[[@R78]--[@R80]\]. The activation of β-catenin and subsequent Wnt pathway signaling reinforces the metastatic state (tumor cell migration, invasion, adhesion) of the cancer cells \[[@R79], [@R81], [@R82]\]. Much evidence has demonstrated the association of heightened β-catenin expression with tumor evolution and poor clinical outcomes \[[@R83]--[@R86]\]. In PC, aberrant β-Catenin expression has been observed and has been shown to have clinical significance with lymph node metastasis. Consistent with previous estimates, Ki-67-positive nuclei clustered heavily in the residual tumors \[[@R9],[@R10]\]. Studies have shown that heightened Ki-67 levels in tumors could directly correlate to reduced time to disease progression after primary therapy, and low OS after systemic (metastatic) recurrence \[[@R87]\]. Furthermore, researchers have reported that a high Ki-67 level in tumors may serve as a stand-alone prognostic factor for progressive disease with metastasis \[[@R88]\], suggesting that metastatic cancers with low and high Ki-67 expression have different median times to progression during therapy.

In residual PC settings, we also identified novel targets, including NKX3.2, PhPTP, MEGF10, and GRB10, that could drive the therapy response in surviving cells. These proteins have not yet been characterized in PC metastasis. However, for the first time, we identified their localization in residual tumors after therapy. These proteins could play a role in orchestrating invasion and metastasis. For example, GRB10, an adaptor protein, has been shown to exhibit Bad-dependent interaction with Raf-1 kinase \[[@R89]\]. Nevertheless, the influence of GRB10 in activating or inhibiting signal transduction and the subsequent functional consequences *in vivo* remain uncertain. Current *in vitro* data from independent studies equivocally support both causal and regulatory roles \[[@R90]--[@R96]\]. MMP-9 has been extensively investigated in tumor metastasis, including PC metastasis. Evidence suggests a directly proportional relationship with elevated overexpression of MMP9 in invasive tumors and their clinical impact on tumor relapse. Nonetheless, HT-EA investigated in this study resulted in the regulation of therapy-associated increased localization of β-catenin, KI-67, NKX3.2, GRB10, Megf10, PhPT-1, and MMP-9 in residual PC models. Our results highlight the molecular blueprint of therapy-induced metastatic signaling and the clinical efficacy of HT-EA in this setting.

The limitation of this study is the use of the PC xenograft residual model. The authors are aware that orthotropic or spontaneous PC models are appropriate to elucidate the molecular events pertaining to invasion and metastasis that occur in tumors and the tumor microenvironment in response to RT. However, the present study was conducted primarily to recognize whether any radio-response in surviving tumor cells activates the metastatic state and to identify any genetic determinants that govern such a phenotype. The xenograft residual PC model utilized in the present study, coupled with the achievability of tumor-specific RT, allowed us to define such function-focused molecular events in PC and recognized the critical role of two candidates, CXCR4 and COX2, in this setting. Armed with this information, our future studies will focus on elucidating the appropriate molecular events in TME with clinically translatable spontaneous PC models that are currently under development in our laboratory.

In conclusion, for the first time, the present study reveals the molecular blueprint for tumor invasion and metastasis in PC cells that survive a course of RT, in *in vitro* (utilizing a panel of genetically diverse human PC cells) and *in vivo* (mouse model of residual PC) settings. Further, the results identified two crucial functional targets, CXCR4 and COX-2, that determine the metastatic state of the surviving PC cells. New to science, the results identified that a high-polarity extraction of seaweed polyphenol, HT-EA, not only mitigates therapy-associated onset of the TIM transcriptome in surviving PC cells and residual tumors, but also selectively targets radiation-induced CXCR4-/COX-2-dependent dissemination destiny of surviving PC cells. Together, the results identified a potential clinically translatable drug deliverable, HT-EA, that could serve as a panacea for PC progression, relapse, and recurrence. Further studies with appropriate residual PC models (spontaneous PC animal models coupled with current clinical treatment modalities), drug pharmacokinetics, and systemic tumor-targeted delivery approaches are warranted and are currently in progress in our laboratory.

MATERIALS AND METHODS {#s4}
=====================

Cell culture {#s4_1}
------------

Human Panc-1 (ATCC-CRL1469), MiaPaCa-2 (ATCC-CRL1420), Panc-3.27 (ATCC-CRL2549), and BxPC-3 (ATCC-CRL1687) cells were obtained from Dr. Daniel J. Brackett (Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK). Low passages of cells were cultured and maintained as described earlier \[[@R40], [@R97]\]. For passaging and for all experiments, the cells were detached using 0.25% trypsin/1% EDTA, resuspended in complete medium, counted electronically using a Countess automated cell counter (Carlsbad, CA, USA), and incubated in a 95% air/5% CO~2~ humidified incubator.

Xenotransplantation mouse model {#s4_2}
-------------------------------

All experiments conformed to American Physiological Society standards for Animal Care, carried out in accordance with the guidelines laid down by the National Research Council, and were approved by our Institutional Animal Care and Use Committee. Seven-week-old male athymic NCr-*nu/nu* nude mice (NCI, Frederick, MD) weighing 25-30 g were acclimated for at least 3 days before the study. Human MiaPaCa-2 (5×10^6^) cells suspended in 30% Matrigel (BD Biosciences) were administered SC into the right flanks. Tumor growth was periodically monitored and tumor volume was calculated using the formula volume = \[(π/6) × length × width^2^\]. Tumors were allowed to grow to a volume of at least 100 mm^3^. Six animals were used in the pretreatment group. Animals were randomly allocated to each group \[[@R98]--[@R102]\]. At the end of each experiment, animals were euthanized by CO~2~ asphyxiation, and the xenografts were harvested and subjected to downstream end-point analysis.

*In vitro* and *in vivo* irradiation procedures {#s4_3}
-----------------------------------------------

In the radiation experiments, cells were exposed to either mock-irradiation or fractionated irradiation (FIR) of 2 Gy/day for 5 days of low-LET using a Gamma Cell 40 Exactor (Nordion International, Inc., Ontario, Canada) at a dose rate of 0.81 Gy/min. *In vivo* PC xenografts were selectively exposed to clinically relevant FIR, (2 Gy/day for 5 days per week for a total of 3 weeks), to a total dose (TD) of 30 Gy. A specially designed cerrobend shield was used to encase the bodies of the mice, exposing only the flank tumors, as described earlier \[[@R53], [@R58], [@R103]\]. Mock-irradiated animals were treated identically, except they were not subjected to radiation.

Polarity gradient polyphenol(s) extraction and cell treatments {#s4_4}
--------------------------------------------------------------

Cells were plated in 100-mm tissue culture plates containing 6 ml of complete growth medium and were allowed to grow up to 70-80% confluence. Polarity-based extractions of seaweed polyphenol fractions were performed as described in our earlier studies \[[@R40]\]. We selectively examined ethyl acetate fraction of *Hormophysa triquerta* (HT-EA). In all *in vitro* investigations, cells were treated with 100 µg/ml of polyphenol, while a corroborated daily (*i.v*.) dose of 10 mg/Kg concentration was used for *in vivo* studies.

Quantitative TIM transcriptome profiling {#s4_5}
----------------------------------------

Total RNA extraction and real-time QPCR profiling were performed as described earlier \[[@R54]\], using a custom-made TIM transcriptome profiler ( [Realtimeprimers.com](http://Realtimeprimers.com), Elkins Park, PA). We started with this highly selective QPCR profiler instead of an all-encompassing gene array because the selected genes entail a well-characterized profile governing TIM. This selection facilitates interpretation of data, simplifying data acquisition and analysis, and avoids genes that are not functionally characterized. The ΔΔ^ct^ values were calculated by normalizing the gene expression levels to the expression of the housekeeping genes. The normalized data were then compared between groups, and the relative expression level of each gene was expressed as fold change. When comparing each gene\'s signal intensity between groups, we used a ≥ 2 fold increase or decrease to represent "stringent" criteria for upregulation or downregulation, and an increase/decrease of \< 2 fold to represent "less stringent" criteria. Classifying gene regulation criteria in this way can provide an index of reliability of the gene expression data \[[@R104]\].

Tissue microarray construction and quantitative immunohistochemistry {#s4_6}
--------------------------------------------------------------------

All mouse tissue microarray construction procedures and automated immunohistochemical (IHC) staining were performed in the Stephenson Cancer Center - Cancer Tissue pathology core, as described earlier \[[@R41], [@R42]\]. For the present study, slides were immunostained for COX2 (Abgent), CXCR4 (Spring Bioscience) GRB10, MEGF10 and MMP9 (Santa Cruz), BAPX1, KI-67 (Thermo Scientific), β-catenin, and PHPT1 (Cell Signaling Technology). Appropriate tissue morphologic/pathologic (H&E) controls and negative controls without primary antibody were examined in parallel. The slides were micro-digitally scanned using an Aperio Scanscope (Aperio Technologies, Inc., Buffalo Grove, IL) slide scanner. Virtual slides were constructed with digital histology. This allows assembly of tissue collections in TMA with variable magnifications. The digital images were then analyzed using Aperio Integrated Spectrum software, the web-based database system. Group-wise comparisons were made using ANOVA with Tukey\'s post-hoc correction. A *P* value of \< 0.05 was considered statistically significant.

Plasmid preparation and DNA/sHRNA transfection {#s4_7}
----------------------------------------------

The plasmid constructs of COX-2 (untagged-Human prostaglandin-endoperoxide synthase 2, Origene) and CXCR4 (untagged-Human chemokine \[C-X-C motif\] receptor 4, Origene) were amplified and purified following the manufacturer\'s protocol. Plasmid DNA transfections were carried out using TurboFectin 8.0 reagent (Origene) as described earlier \[[@R105]\]. COX2 silencing of was achieved with MISSION COX-2 shRNA (CCG GCT ATC ACT TCA AAC TGA AAT TCT CGA GAA TTT CAG TTT GAA GTG ATA GTT TTT G), while CXCR4 silencing was achieved using MISSION CXCR4 shRNA (CCG GGC GTG TAG TGA ATC ACG TAA ACT CGA GTT TAC GTG ATT CAC TAC ACG CTT TTT G; Sigma-Aldrich). Transfected cells were either mock-IR, exposed to IR, or treated with HT-EA, and were utilized for determining tumor cell invasion and migration.

Real-time wound-healing assay {#s4_8}
-----------------------------

ORIS™ cell migration assay (Platypus Technologies, Madison, WI) was used to examine the alterations in PC cell migration in response to the mock-irradiation, IR exposure with/without HT-EA treatment, IR exposure with/without COX-2/CXCR4 silencing, and forced expression of COX-2/CXCR4, with/without HT-EA treatment following manufacturer\'s protocol. Induced or associated modification in cellular proliferation was arrested using Mitomycin C (10 μg/ml, Sigma). Cells were stained with CellTracker™ CMFDA (5-chloromethylfluorescein diacetate), Thermo Fisher Scientific, Waltham. MA), a Green-fluorescent dye, and were imaged in real-time at 0h and at 24 h using an Operetta high-content confocal immunofluorescence imager (Perkin Elmer, Inc., Waltham, MA).

Matrigel invasion assay {#s4_9}
-----------------------

For invasion assays, 1× 10^5^ cells were plated in the top chamber with a Matrigel-coated membrane (24-well insert; pore size, 8 μm; BD Biosciences). Cells were plated in medium without serum, and medium supplemented with serum was used as a chemoattractant in the lower chamber. The cells were incubated for 24 h. Cells that did not migrate or invade through the pores were removed by a cotton swab. Cells on the lower surface of the membrane were fixed with 3:1 methanol: acetic acid and stained using 0.1% Crystal violet to visualize the invaded cells.
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